343 related articles for article (PubMed ID: 26438248)
21. Biomacromolecular carriers based hydrophobic natural products for potential cancer therapy.
Pan W; Gu F; Yan X; Huang J; Liao H; Niu F
Int J Biol Macromol; 2024 Jun; 269(Pt 2):132274. PubMed ID: 38734357
[TBL] [Abstract][Full Text] [Related]
22. Role of Nanotechnology in Overcoming the Multidrug Resistance in Cancer Therapy: A Review.
Mir SA; Hamid L; Bader GN; Shoaib A; Rahamathulla M; Alshahrani MY; Alam P; Shakeel F
Molecules; 2022 Oct; 27(19):. PubMed ID: 36235145
[TBL] [Abstract][Full Text] [Related]
23. Co-delivery nanoparticles of anti-cancer drugs for improving chemotherapy efficacy.
Qi SS; Sun JH; Yu HH; Yu SQ
Drug Deliv; 2017 Nov; 24(1):1909-1926. PubMed ID: 29191057
[TBL] [Abstract][Full Text] [Related]
24. Nanotechnology-based approaches overcome lung cancer drug resistance through diagnosis and treatment.
Li J; Zhu L; Kwok HF
Drug Resist Updat; 2023 Jan; 66():100904. PubMed ID: 36462375
[TBL] [Abstract][Full Text] [Related]
25. The spatiotemporal journey of nanomedicines in solid tumors on their therapeutic efficacy.
Qin M; Xia H; Xu W; Chen B; Wang Y
Adv Drug Deliv Rev; 2023 Dec; 203():115137. PubMed ID: 37949414
[TBL] [Abstract][Full Text] [Related]
26. Engineered Nanoparticles Against MDR in Cancer: The State of the Art and its Prospective.
Ahmad J; Akhter S; Greig NH; Kamal MA; Midoux P; Pichon C
Curr Pharm Des; 2016; 22(28):4360-4373. PubMed ID: 27319945
[TBL] [Abstract][Full Text] [Related]
27. Functionalized Carbon Nanostructures Versus Drug Resistance: Promising Scenarios in Cancer Treatment.
Curcio M; Farfalla A; Saletta F; Valli E; Pantuso E; Nicoletta FP; Iemma F; Vittorio O; Cirillo G
Molecules; 2020 Apr; 25(9):. PubMed ID: 32365886
[TBL] [Abstract][Full Text] [Related]
28. The potential of multi-compound nanoparticles to bypass drug resistance in cancer.
Da Silva CG; Peters GJ; Ossendorp F; Cruz LJ
Cancer Chemother Pharmacol; 2017 Nov; 80(5):881-894. PubMed ID: 28887666
[TBL] [Abstract][Full Text] [Related]
29. High drug-loading nanomedicines: progress, current status, and prospects.
Shen S; Wu Y; Liu Y; Wu D
Int J Nanomedicine; 2017; 12():4085-4109. PubMed ID: 28615938
[TBL] [Abstract][Full Text] [Related]
30. Development of individualized anti-metastasis strategies by engineering nanomedicines.
He Q; Guo S; Qian Z; Chen X
Chem Soc Rev; 2015 Oct; 44(17):6258-86. PubMed ID: 26056688
[TBL] [Abstract][Full Text] [Related]
31. Nanoparticle formulations of cisplatin for cancer therapy.
Duan X; He C; Kron SJ; Lin W
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2016 Sep; 8(5):776-91. PubMed ID: 26848041
[TBL] [Abstract][Full Text] [Related]
32. Mannose and Mannose-6-Phosphate Receptor-Targeted Drug Delivery Systems and Their Application in Cancer Therapy.
Dalle Vedove E; Costabile G; Merkel OM
Adv Healthc Mater; 2018 Jul; 7(14):e1701398. PubMed ID: 29719138
[TBL] [Abstract][Full Text] [Related]
33. Paradigm shift in bacteriophage-mediated delivery of anticancer drugs: from targeted 'magic bullets' to self-navigated 'magic missiles'.
Petrenko VA; Gillespie JW
Expert Opin Drug Deliv; 2017 Mar; 14(3):373-384. PubMed ID: 27466706
[TBL] [Abstract][Full Text] [Related]
34. Image-guided nanosystems for targeted delivery in cancer therapy.
Iyer AK; He J; Amiji MM
Curr Med Chem; 2012; 19(19):3230-40. PubMed ID: 22612697
[TBL] [Abstract][Full Text] [Related]
35. Nanomedicine Combats Drug Resistance in Lung Cancer.
Zheng X; Song X; Zhu G; Pan D; Li H; Hu J; Xiao K; Gong Q; Gu Z; Luo K; Li W
Adv Mater; 2024 Jan; 36(3):e2308977. PubMed ID: 37968865
[TBL] [Abstract][Full Text] [Related]
36. Engineering lactate-modulating nanomedicines for cancer therapy.
Chen J; Zhu Y; Wu C; Shi J
Chem Soc Rev; 2023 Feb; 52(3):973-1000. PubMed ID: 36597879
[TBL] [Abstract][Full Text] [Related]
37. Cancer chemotherapy resistance: Mechanisms and recent breakthrough in targeted drug delivery.
Davodabadi F; Sajjadi SF; Sarhadi M; Mirghasemi S; Nadali Hezaveh M; Khosravi S; Kamali Andani M; Cordani M; Basiri M; Ghavami S
Eur J Pharmacol; 2023 Nov; 958():176013. PubMed ID: 37633322
[TBL] [Abstract][Full Text] [Related]
38. Recent Trends in Nanomedicine-Based Strategies to Overcome Multidrug Resistance in Tumors.
Khan MM; Torchilin VP
Cancers (Basel); 2022 Aug; 14(17):. PubMed ID: 36077660
[TBL] [Abstract][Full Text] [Related]
39. Single Molecular Nanomedicines Based on Macrocyclic Carrier-Drug Conjugates for Concentration-Independent Encapsulation and Precise Activation of Drugs.
Yao SY; Ying AK; Jiang ZT; Cheng YQ; Geng WC; Hu XY; Cai K; Guo DS
J Am Chem Soc; 2024 May; 146(20):14203-14212. PubMed ID: 38733560
[TBL] [Abstract][Full Text] [Related]
40. Recent advances in access to overcome cancer drug resistance by nanocarrier drug delivery system.
Sun X; Zhao P; Lin J; Chen K; Shen J
Cancer Drug Resist; 2023; 6(2):390-415. PubMed ID: 37457134
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
